CD274 and non-small cell lung carcinoma: Following the approval of pembrolizumab as the frontline treatment for advanced and metastatic non-small cell lung cancers (NSCLC) patients who are PD-L1 positive, neoadjuvant use of anti-PD-L1/PD-1 antibody has been exploited (1).